BIOMAT Database Logo BIOMAT Database Logo

Immunohistology of liver allografts in recipients managed with prophylactic OKT3. 1989

R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Department of Surgery, New England Medical Center, Boston, MA 02111.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008775 Methylprednisolone A PREDNISOLONE derivative with similar anti-inflammatory action. 6-Methylprednisolone,Medrol,Metipred,Urbason,6 Methylprednisolone
D011897 Random Allocation A process involving chance used in therapeutic trials or other research endeavor for allocating experimental subjects, human or animal, between treatment and control groups, or among treatment groups. It may also apply to experiments on inanimate objects. Randomization,Allocation, Random
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D003524 Cyclosporins A group of closely related cyclic undecapeptides from the fungi Trichoderma polysporum and Cylindocarpon lucidum. They have some antineoplastic and antifungal action and significant immunosuppressive effects. Cyclosporins have been proposed as adjuvants in tissue and organ transplantation to suppress graft rejection. Cyclosporines
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006084 Graft Rejection An immune response with both cellular and humoral components, directed against an allogeneic transplant, whose tissue antigens are not compatible with those of the recipient. Transplant Rejection,Rejection, Transplant,Transplantation Rejection,Graft Rejections,Rejection, Graft,Rejection, Transplantation,Rejections, Graft,Rejections, Transplant,Rejections, Transplantation,Transplant Rejections,Transplantation Rejections
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001379 Azathioprine An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed) Azathioprine Sodium,Azathioprine Sodium Salt,Azathioprine Sulfate,Azothioprine,Immuran,Imuran,Imurel,Sodium, Azathioprine

Related Publications

R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Lymphocyte parameters in liver graft recipients receiving prophylactic OKT3 or conventional triple therapy.
February 1989, Transplantation proceedings,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
[In vivo use of OKT3 monoclonal antibodies in recipients of renal allografts].
January 1987, Nephrologie,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Induction therapy with OKT3 in pediatric liver-transplant recipients.
December 1994, Transplantation science,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Accelerated liver allograft rejection during prophylactic immunosuppression with OKT3.
January 1993, Transplantation,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
One-month prophylactic use of OKT3 in cadaver kidney transplant recipients.
March 1988, Transplantation,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Anti-OKT3 response following prophylactic treatment in paediatric kidney transplant recipients.
June 1993, Pediatric nephrology (Berlin, Germany),
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Prophylactic use of OKT3 in liver transplantation. A review.
October 1991, Digestive diseases and sciences,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Prophylactic use of OKT3 in immunologic high-risk cadaver renal transplant recipients.
November 1989, American journal of kidney diseases : the official journal of the National Kidney Foundation,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
Prophylactic use of OKT3 monoclonal antibody in cadaver kidney recipients. Utilization of OKT3 as the sole immunosuppressive agent.
June 1986, Transplantation,
R J Rohrer, and R L Jenkins, and U Khettry, and C W Pinson, and C Gallik-Karlson, and A P Monaco
OKT3 as prophylaxis immunosuppression in pediatric liver transplant recipients.
February 1994, Transplantation proceedings,
Copied contents to your clipboard!